Table 2. Adjusted hazard ratios (HRs) for ankylosing spondylitis according to hs-CRP concentrations at baseline, using different models and sensitivity analyses.
| Plasma concentrations of hs-CRP (mg/L) | |||||
|---|---|---|---|---|---|
| Model | <1.00 | 1.00–2.99 | 3.00–9.99 | ≥10.0 | P for trend |
| Age- and sex-adjusted model | 1.00 | 1.15 (0.48–2.75) | 4.25 (2.06–8.77) | 18.2 (8.9–37.3) | <0.001 |
| Multivariate model 1a | 1.00 | 1.22 (0.51–2.90) | 4.50 (2.17–9.33) | 19.2 (9.3–39.4) | <0.001 |
| Multivariate model 2b | 1.00 | 1.28 (0.54–3.08) | 4.71 (2.26–9.81) | 19.8 (9.6–40.9) | <0.001 |
| Sensitivity analysesb | |||||
| Using cumulative average hs-CRP | 1.00 | 1.48 (0.61–3.58) | 7.0 (3.2–15.5) | 51.6 (22.9–116.2) | <0.001 |
| 2-year-lag analysis | 1.00 | 2.24 (0.72–7.00) | 7.8 (2.9–21.1) | 29.5 (10.8–80.0) | <0.001 |
| Excluding smokers | 1.00 | 2.22 (0.64–7.79) | 4.5 (1.3–16.0) | 49.8 (17.3–143.4) | <0.001 |
hs-CRP, high-sensitivity C-reactive protein. Data presented are hazard ratios relative to <1.00 mg/L hs-CRP, with 95% confidence intervals.
aModel adjusted for age, sex, education, average monthly income of each family member, smoking, alcohol intake, and physical activity.
bModel included the variables in model 1, and was further adjusted for body mass index, blood-pressure status, blood glucose status, total cholesterol, history of cardiovascular disease, and use of antihypertensives, lipid-lowering agents, and aspirin.